Objectives: Despite the importance of achieving tight control, many rheumatoid arthritis (RA) patients are not effectively treated with disease modifying anti-rheumatic drugs (DMARDs). The objective of this study was to develop a decision support tool to inform RA patients with ongoing active disease about the risks and benefits related to biologic therapy.
demonstrated that this theory falls short in predicting how people make decisions in the real world (9) (10) (11) (12) . Fuzzy trace theory (FTT) builds directly on the advances of earlier research in risk perception and medical decision making to provide a more useful framework to guide the development of intuitive decision aids for patients (9, (13) (14) (15) . FTT contends that people code and retrieve information using gist and verbatim representations. In this context, gist refers to the overall picture or the general meaning that people attach to a specific medication characteristic (9) . Gist is qualitative, subjective, and dependent on individual factors (e.g. education, culture and experience) that affect meaning. For example, the gist representation of the extremely rare risk of progressive multifocal leukoencephalopathy for one patient might be "I could get something like mad cow disease and die" and for another patient "bad things can happen with all medications, but this is really rare and unlikely to happen to me." In contrast, verbatim representations refer to the literal risk. A large body of evidence based on studies using controlled experiments, mathematical models, and neuroimaging, supports the conclusion that people preferentially rely on gist, and not verbatim, representations when making decisions (9, 14) . For example, knowing one's precise risk of developing breast cancer (verbatim representation) does not increase the rate of screening. In contrast, perceived risk (i.e., "my risk is high," a gist representation) is a much stronger predictor of health-related behaviors (16, 17) .
Currently, no proven mechanisms exist to effectively inform RA patients and enable them to process the complex information related to escalating care after failing traditional disease modifying anti-rheumatic drugs (DMARDs). The objective of this study was to develop a theory-based decision tool to effectively inform patients and promote high quality decision making in RA patients who are candidates for biologic disease-modifying drugs. Informed choice requires that patients accurately understand salient differences between available treatment options. More important than being able to recall precise "verbatim" risk estimates, is the ability to attach accurate meaning to this information (9, 14) .
METHODS

Tool Design
The tool is an interactive, web-based, computerized educational module with voice-overs that subjects navigate through using a menu bar. Information is provided for all tumor necrosis factor inhibitors, abatacept, rituximab and tocilizumab. To promote accurate gist representations, the tool begins with an educational segment describing the natural history of RA and why biologics are frequently recommended for patients with persistent disease activity despite the use of traditional DMARDs. The introduction's objective is to ensure that subjects have accurate illness perceptions regarding the consequences of chronic inflammation and the role of biologics.
Because the amount of information can influence risk perceptions (18, 19) , the same amount of attention was devoted to benefits as was to risks. Benefits included improvements in pain, joint swelling, fatigue, progression of erosions, chance of remission, sleep disturbance, cardiovascular outcomes, work, and overall quality of life. Links were provided to view bar graphs demonstrating the benefit of adding the specific biologic to a traditional DMARD (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
We surveyed a panel of 13 internationally renowned RA experts and, based on their ratings, stratified AEs into those that: 1) must be disclosed to all patients considering biologics, 2) should be provided as supplemental information via links for patients desiring additional information, and 3) need not be included at all. This flexible approach addresses needs of patients desiring additional information without overwhelming others.
The expert panel was presented with three groups of AEs: not serious and easily reversible, moderately serious and requiring treatment, and those associated with significant morbidity. Experts rated the AEs from "Extremely important" (1) to "Not important at all" (7). AEs were treated per the following rules:
Step 1: If over 75% of the panel rated the AE between 5 and 7, the AE was excluded from the tool. The remaining AEs were included if 75% or more of the panel rated the AE between 1 and 4; otherwise, they were included as a link. Graphics were used to facilitate understanding of probabilistic information. Pie charts (for AEs with a risk of 1% or greater) and pictographs (for AEs occurring in less than 1%) were used to describe AEs and to specifically prevent denominator neglect (39) . We also inserted questions to test patient knowledge and provide feedback. Knowledge questions emphasized accurate gist representations and not recall of specific "verbatim" data. After subjects responded, feedback highlighted the correct response. Illustrative screen shots are provided in the Appendix.
Pre-Post Test
Subjects were recruited from community-based rheumatology practices. Potential subjects were referred by their treating physician and screened for eligibility. Subjects who were at least 18 years of age; able to speak and read English; were taking one or more traditional DMARDs and/or using a biologic (including rituximab in the last 12 months) were eligible to participate.
We did not exclude patients currently on a biologic because, except for optional links which demonstrate graphs comparing biologics + methotrexate to methotrexate alone, the tool content is also relevant for patients considering switching to a new biologic. For example, while the tool defaults to first presenting tumor necrosis factor inhibitors, a navigation bar allows subjects to choose tabs linking to a different biologic. In view of the literature demonstrating that patients are frequently under-informed about their medications, we expected the information included in the tool to also be relevant to subjects currently using a biologic (40) .
Given the timeline and budget for this study, it was not possible to recruit patients at the time of an actual treatment decision. Ideally, because the tool is designed to complement patient-physician communication, physicians would refer patients to access the tool after discussing the need to consider escalating care. Implementing the tool in this setting, however, requires significant resources and is better justified once preliminary data support its potential value.
Exclusion criteria included relative or absolute contraindications to any approved biologic (class III or IV congestive heart failure, open skin wound, active infection, history of demyelinating disease, untreated latent tuberculosis); co-morbidities that may overwhelm RA treatment decisions (e.g., history of malignancy within the past five years, excluding basal cell carcinoma, end-stage renal disease on dialysis, end-stage chronic obstructive pulmonary disease, or hearing or visual impairment).
Data Collection
RA patients participated in a single face-to-face interview during which they completed questionnaires before and after viewing the tool. We measured change in knowledge, perceived knowledge and values clarification (41), willingness to try biologics (42) and value-concordant choices. Values were assessed as simple gist principles (9, 14, 15) . Because no questionnaires existed to measure patient knowledge related to biologics, we developed 20 True/False statements (10 each; Appendix). Items were pilot tested to ensure comprehension. Item order was determined using a random-numbers generator. Perceived knowledge and clarity of values were measured using two subscales from the well-validated Decisional Conflict Scale (41).
These six items are coded on 5-point scales ranging from "Strongly agree" to "Strongly disagree." The perceived knowledge items are: "I know which options are available to me; I know the benefits of each option; I know the risks and side effects of each option." The clarity of values items are: "I am clear about which benefits matter most to me; I am clear about which risks and side effects matter most to me; I am clear about which is more important to me (the benefits or the risk and side effects.)" Patients' willingness to take a (new) biologic was measured using the choice predisposition scale (42) : "If your doctor recommended that you consider taking a (new) biologic, would you be willing to take one?" This item is coded on an 11-point scale anchored by "Not willing at all " and "Extremely willing" with "Unsure" at the midpoint (42) .
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Although no currently available instruments exist to measure informed choice, there is agreement that such choice is based on accurate knowledge that is concordant with one's values (43) . Thus, we classified subjects as having made an informed choice based on a priori criteria set before enrollment: 1) they answered 75% of the knowledge items correctly, were willing to try a (new) biologic as indicated by a choice predisposition score of 8 or greater, and had values that favored the use of medications to control disease activity; or 2) they answered (44) (45) (46) . Acceptability of the tool was assessed by asking subjects to rate the quality, quantity, and balance of information presented (5-point scale ranging from "Excellent" to "Very poor"); whether they thought the tool was helpful for learning about biologics ("Very helpful", "Somewhat", "Not helpful") and whether they would recommend the tool for other patients ("Yes"; "No").
Analysis
Statistical analyses were conducted with SAS software (Version 9.22). Pre-post test differences for continuous variables were performed using paired t-tests. The proportion of subjects having a value-concordant choice before and after completing the tool was compared using McNemar's test. Pre-post test differences, including baselines scores, were also examined using general linear models to adjust for age, education, disease activity (RAPID-4 score) and current biologic use (47).
The study was powered to detect a difference in the pre-post perceived knowledge scores because it has been shown to discriminate between patients who reject or accept medical interventions (41) . Based on previous studies, 90 subjects were needed to detect a Cohen's d effect size of at least 0.3 (41) assuming a correlation between ratings r = 0.5, alpha = 0.05, 80% power, and 2-tailed test.
This protocol was determined to be exempt from continuing review by the Human Investigations Committee at our institution. Verbal consent was obtained from all participants.
RESULTS
We interviewed 104 subjects (48 eligible subjects refused to participate), mean age (SD) 62 (12) years. The majority of subjects were White (87%), female (84%) and had some college education (72%). Thirty-nine percent were employed, 40% were retired, 15% were on disability, and 6% were unemployed. The median (range) duration of RA was eight years (1-61) and the median (range) RAPID4 score was 16.1 (4.3-31.2). Thirty-eight percent reported overall health Table 2) . Subjects were more willing to try a biologic after viewing the tool [mean (SD) difference = 1.4 (2.3)] ( Table 2 ). Improvements were seen in subjects who were, and were not, currently on a biologic ( Table 3 ). The proportion of subjects making an informed, value-concordant choice significantly increased from 35% to 64% (p=0.0001). The proportion of subjects making an informed, value-concordant choice improved from 29% to 56% (p=0.001) among subjects who were not currently on a biologic, and from 44% to 78% among those who were currently on a biologic (p=0.002).
Pre-post test differences, measured using general linear models including baseline scores, are presented in Table 4 . Improvements in knowledge were similar in older (65 years or older) and younger adults (64 years or younger). Statistically significant improvements in knowledge were seen across education levels, but those with less than a college education benefited more than those with at least some college education (mean (SD) difference = 3.3 Increased willingness to try a biologic was greater among subjects with at least some college education (mean (SD) difference = 1.7 (2.3), p<0.0001) compared to those without such education (mean (SD) difference = 0.7 (1.9), p=0.05) and among younger adults (mean difference (SD) = 2.0 (2.4), p<0.0001) compared to older adults (mean (SD) difference = 0.6 (1.7), p=0.05) ( Table 4 , Figures 1 and 2 ). 
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Over 90% of participants rated the quality and quantity of information as very good or excellent. Eighty-nine percent found the tool to be very helpful and 100% would recommend it for patients with RA.
DISCUSSION
Based on principles of FTT, a tool to support decision making for RA patients who are candidates for biologic therapy, significantly increased knowledge, decreased decisional conflict (improved perceived knowledge and clarification of values), and increased patient willingness to escalate care in a pre-post test. Most importantly, the tool increased the proportion of patients making an informed, value-concordant choice by over 80%.
Decision aids have largely focused on supporting patient decision making in situations that include at least two plausible treatment options (including the possibility in some cases of refusal or deferral) and choice depends on individual patient preferences. Widely studied examples include treatment for early-stage breast and prostate cancer, screening for colorectal cancer, and the decision to undergo elective orthopedic surgery. These decisions are considered "preference-sensitive" because neither option clearly dominates. In contrast, escalating care for RA patients with ongoing active disease is a decision in which the benefits clearly outweigh the risks for the vast majority of patients, yet biologics are nonetheless underused. Data suggest that patient and physician-related factors are responsible. Wolfe et al (6) found that fear of losing control over their disease and fear of AEs both contribute to patients' reluctance to change therapy, even when clinically indicated. van Hulst et al (7) recently found that patients and physicians differ substantially in how they approach the decision of whether or not to escalate care and suggested that better patient-physician communication is needed to improve decision making.
In this study, we addressed barriers impeding adherence to the principles of tight control.
We took several steps to overcome patients' bias towards maintaining the status quo. We devoted as much attention to the benefits associated with biologics as to the risks and we included graphs to ensure that patients attended to denominators, which include the number of patients who do not experience an AE. Our results suggest that these efforts were successful in improving knowledge and in helping patients clarify their values. Improving patient knowledge and clarity of values is necessary to prepare patients to better communicate with their physicians. While we did not measure actual behavior change in this study, we did find that willingness to try a biologic also significantly increased after viewing the tool. Most importantly, the tool significantly increased the likelihood of making an informed, value-concordant choice.
Improvements were seen across demographic groups, although some differences were larger for subgroups. Specifically, subjects without a college education demonstrated greater improvements in knowledge compared to those with at least some college. The fact that those with less education significantly improved is an encouraging finding, and suggests that the tool was constructed at a level that will benefit subjects across a wide range of backgrounds, including those most in need. Twenty-four percent of subjects without a college education scored 18 or higher (maximum score=20) on the baseline knowledge assessment compared to 44% of subjects with a college education. Thus, the difference noted may be due in part to a ceiling effect among those with a college education. It is possible that people with college education who were already on a biologic (40% in our sample) were more likely to have already sought information about biologics than those without college education. We also found that, despite significant improvements in objective/perceived knowledge and values clarification, older adults were less likely than their younger counterparts to be willing to escalate care. This finding is consistent with some papers reporting greater risk aversion among older adults (48, 49) . However, others have failed to find a significant association between age and treatment preference (50, 51) , suggesting that this relationship is likely context specific.
There are several limitations of this study. The majority of the subjects had a college education and most were White, thereby limiting the generalizability of the results. In addition, The decision support tool described in this paper was designed based on strong theoretical principles, and pre-post testing demonstrates that it successfully promotes valid gist representations, facilitates processing of tradeoffs, and enables patients to understand the salient differences between the treatment options available to them. 
Negative
It is better to take natural remedies than prescription medications for my arthritis.
(0.7)
Negative It is wrong to take medications for my arthritis that could cause serious side effects.
(0.8) Positive
It is important to take care of my disease so that I can be as productive as possible.
(0.7)
Statements are coded on a 1-4 scale with 1 = strongly agree and 4 = strongly disagree. 
